Navigation Links
STAAR Surgical Receives Approval to Market Visian(R) Toric Implantable Collamer Lens in China
Date:2/29/2008

STAAR ALSO RECEIVES APPROVAL TO MARKET HYPEROPIC ICL

APPROVALS POSITION COMPANY FOR CONTINUED GROWTH IN KEY MARKET

MONROVIA, Calif., Feb. 29 /PRNewswire-FirstCall/ -- STAAR Surgical Company (Nasdaq: STAA), a leading developer, manufacturer and marketer of minimally invasive ophthalmic products, today announced it has received approval from the State Food and Drug Administration of the People's Republic of China (SFDA) to market the STAAR Visian(TM) Toric Implantable Collamer Lens to ophthalmologists and other eye care professionals in the country for the treatment of nearsightedness and astigmatism. In addition the SFDA granted approval to STAAR to market the STAAR Visian ICH, an implantable collamer lens to correct hyperopia or farsightedness.

"This approval has significant strategic importance for STAAR and positions us for continued growth in China," said Barry G. Caldwell, President and CEO of STAAR Surgical. "The approval of both the Visian Toric ICL and the Visian Hyperopic ICL represents a solid endorsement of the STAAR technology. The Visian Myopic ICL was approved in China during July 2006 and has enjoyed significant growth. With these additional approvals, we are positioned to expand our presence in a market where the demographics are very favorable."

According to Market Scope, a leading source for ophthalmic market data, there are over 500 million myopes and nearly 50 million hyperopes in China making it the largest potential refractive market in the world. In South Korea, where the population is believed to have a mean myopia rate similar to that of China, phakic implant procedures are estimated to have reached seven percent of the LASIK market. According to data presented at an ophthalmic meeting in Japan during January, STAAR's Visian ICL and TICL were used in approximately 60% of those procedures. "Our goal in China over time is to at least replicate the market penetration we are achieving in South Korea," Mr. Caldwell added.

Made of STAAR's proprietary, highly biocompatible Collamer(R) material, the ICL, TICL and the ICH are the only minimally invasive foldable lenses of their kind approved for the Chinese commercial market. As a result of the unique foldable design, the ICL procedure allows an incision up to 50% smaller than competing technology, and its placement in the eye behind the iris provides a more aesthetically pleasing outcome. These approvals in China are for treatments of myopic patients with refractive errors between -3.00 and -20.0 and astigmatism up to six diopters. The hyperopic approval is for patients with refractive errors between +1.0 to +4.0.

About STAAR Surgical

STAAR is a leader in the development, manufacture and marketing of minimally invasive ophthalmic products employing proprietary technologies. STAAR's products are used by ophthalmic surgeons and include the Visian ICL, a tiny, flexible lens implanted to correct refractive errors, as well as innovative products designed to improve patient outcomes for cataracts and glaucoma. Manufactured in Switzerland by STAAR, the ICL is approved by the FDA for use in treating myopia, has received CE Marking and is sold in more than 40 countries. More information is available at http://www.staar.com.

Safe Harbor

All statements in this press release that are not statements of historical fact are forward-looking statements, including any statements of the plans, strategies, and objectives of management for future operations, any statements regarding expectations for success of the ICL, TICL or other products in China, the U.S. or other markets, statements of belief and any statements of assumptions underlying any of the foregoing. These statements are based on expectations and assumptions as of the date of this press release and are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those described in the forward-looking statements. The risks and uncertainties include our limited capital resources and limited access to financing, the challenge of managing foreign subsidiaries, the willingness of surgeons and patients to adopt a new product and procedure and other factors beyond our control, including those detailed from time to time in our reports filed with the Securities and Exchange Commission. STAAR assumes no obligation to update these forward-looking statements to reflect future events or actual outcomes and does not intend to do so.

CONTACT: Investors Media

EVC Group EVC Group

Douglas Sherk, 415-896-6820 Steve DiMattia, 646-277-8706

Matthew Selinger, 415-896-6817


'/>"/>
SOURCE STAAR Surgical
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. New Orthopedic Surgical Robotics Company Opens Its Doors; Files with the FDA for Clearance of Its Flagship Product
2. CryoLife Signs Distribution Agreement for Inclusion of BioGlue(R) Surgical Adhesive in Hernia Repair Kit with Proxy Biomedical Surgical Meshes
3. MAKO Surgical Corp. Files Registration Statement for Initial Public Offering of Common Stock
4. National Surgical Hospitals Acquires Majority Share of Houston-Area Surgery Center
5. Surgical and Trauma Wound Care Market to Tie Up $7 Billion in Sales by 2011
6. Cardica and Intuitive Surgical to Host Educational Symposium on Advanced Techniques and Technologies in Robotic Coronary Revascularization and Mitral Valve Repair
7. Arbor Surgical Technologies Announces Series C Financing and Licensing Agreement with Medtronic
8. Sunnylife Global Announces Completion of Surgical Wing of Xiang Tan World Friendship Hospital
9. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
10. Ciphergen Biosystems Receives Noncompliance Letter From The Nasdaq Stock Market
11. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... the release of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” ... and retention in this eBook by providing practical tips, tools, and strategies for ...
(Date:6/23/2016)... , June 23, 2016 Houston Methodist ... the Cy-Fair Sports Association to serve as their ... agreement, Houston Methodist Willowbrook will provide sponsorship support, ... connectivity with association coaches, volunteers, athletes and families. ... the Cy-Fair Sports Association and to bring Houston ...
(Date:6/23/2016)... ... June 23, 2016 , ... Supplyframe, the ... the Supplyframe Design Lab . Located in Pasadena, Calif., the Design Lab’s ... how hardware projects are designed, built and brought to market. , The Design ...
(Date:6/23/2016)... LONDON , June 23, 2016 ... & Hematology Review, 2016;12(1):22-8 http://doi.org/10.17925/OHR.2016.12.01.22 ... Review , the peer-reviewed journal from touchONCOLOGY, ... the escalating cost of cancer care is placing ... a result of expensive biologic therapies. With the ...
Breaking Biology Technology:
(Date:4/28/2016)... FRANCISCO and BANGALORE, India , ... of EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... provider, today announced a global partnership that will ... way to use mobile banking and payment services. ... is a key innovation area for financial services, but it ...
(Date:4/15/2016)... , April 15, 2016  A new partnership ... more accurate underwriting decisions in a fraction of ... competitively priced and high-value life insurance policies to ... With Force Diagnostics, rapid testing (A1C, ... data readings (blood pressure, weight, pulse, BMI, and ...
(Date:3/31/2016)... PROVIDENCE, R.I. , March 31, 2016  Genomics ... leadership of founding CEO, Barrett Bready , M.D., ... addition, members of the original technical leadership team, including ... Vice President of Product Development, Steve Nurnberg and Vice ... have returned to the company. Dr. Bready ...
Breaking Biology News(10 mins):